Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076   CADENCE PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts)Three Months EndedMarch 31,20132012Revenue:Product revenue, net

$
23,612$
8,004Total revenues

23,6128,004Costs and expenses:Cost of product sales

8,1674,246Amortization of patent license

336336Research and development

1,3631,511Selling, general and administrative

21,63523,531Other

50-Total costs and expenses

31,55129,624Loss from operations

(7,939)(21,620)Other income (expense), net

6,576(1,053)Net loss

$
(1,363)$
(22,673)Basic and diluted net loss per share

$
(0.02)$
(0.27)Shares used to compute basic anddiluted net loss per share

85,67285,519 CADENCE PHARMACEUTICALS, INC.CONDENSED BALANCE SHEETS(in thousands)March 31,December 31,20132012(unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments 

$
4,240$
2,072Restricted cash 

640640Accounts receivable, net 

8,9086,152Inventory 

6,0836,498Prepaid expenses and other current assets 

2,0411,154Total current assets

81,91276,516Property and equipment, net

1,9051,967Intangible assets, net

11,75412,090Other assets

907,106Total assets

$
95,661$
97,679Liabilities and Stockholders' Equity Current liabilities:Accounts payable 

$
5,808$
5,796Accrued liabilities 

12,53212,969Deferred revenue 

-2,234Current debt, less discount 

2,552-Total current liabilities

20,89220,999Other liabilities

23351Long-term debt, less discount

26,38828,818Total stockholders' equity

48,14847,811Total liabilities and stockholders' equity

$
95,661
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014 Silicon Valley Electronic Data ... RPM Alliance , provider of clinical research and ... the latest addition to its CRO Partnership Program, Clinovo ... system to India. , “We have found Clinovo’s ... customizable EDC platform which is both user friendly and ...
(Date:11/26/2014)... SoundConnect , an award winning unified ... that Darren Suders has joined the team as Director ... the partner program through innovative offerings, consistent ... Darren brings more than 10-years of channel telecommunication experience ... operations, from policy development, to partner education and to ...
(Date:11/26/2014)... , 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation ... il mercato europeo in occasione di Hi Europe 2014 ... ). Si tratta della curcumina con la ... amorfa (senza cristalli) e ingredienti approvati dalle norme europee. ... nella spezia della pianta curcumina ( Curcuma longa ) ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... diagnostic tests for cancer and other conditions, today announced that ... at the Science for Business BioWin Day 2014, being held ... The data come from VolitionRx,s lung cancer pilot study, the ... the Centre Hospitalier Universitaire (CHU) de Liege in ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Inc. (OTC Bulletin Board: CSBR ), a ... and tumor specific data to enhance the value of ... joined the management team as the Chief Executive Officer ... Dr. Ronnie Morris will join the management team as ...
... Oct. 28 Q3 2010 Change on a reported ... 9 months 2010Change on a reported ... sales , €7,821m+5.7% , -1.7% , €22,989m+4.8% , ... €7,377m+8.7% , +6.0%Business EPS(1)€1.89+8.6%-2.3%€5.65+8.7%+6.0% In order to facilitate an understanding ...
Cached Biology Technology:Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 2Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 3Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 4Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 5Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 6Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 7Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 8Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 9Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 10Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 11Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 12Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 13Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 14Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 15Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 16Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 17Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 18Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 19Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 20Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 21Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 22Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 23Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 24Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 25Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 26Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 27Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 28Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 29Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 30Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 31Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 32Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 33Champions Biotechnology Reports Additions to its Management Team 2Champions Biotechnology Reports Additions to its Management Team 3Champions Biotechnology Reports Additions to its Management Team 4
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 4, 2010 -- Supercomputer simulations at the Department of Energy,s ... acids could have contributed to the origins of life. ... directs ORNL,s Center for Molecular Biophysics and holds a Governor,s ... probe an organic chemical reaction that may have been important ...
... Rockville, MD, USA (October 4, 2010) The ... receipt of a grant from the United States Food ... immunological biomarkers for TB vaccine development. The FDA grant, ... researchers from the United States, the United Kingdom and ...
... Ben Major, PhD, assistant professor of cell and developmental ... of Health Director,s New Innovator Awards, one of the ... will fund his work to address a significant medical ... functionally contribute to specific cellular and disease processes such ...
Cached Biology News:Powerful supercomputer peers into the origin of life 2Aeras-led research consortium receives FDA support 2UNC scientist receives NIH director's New Innovator Award 2
... to the Salmonella Common Structural Antigens (CSA) ... serum pool of goats immunized with different ... broadly reactive to Salmonella and recognizes all ... excellent specificity for Group B and D ...
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... products into 1:, , A multi-tube homogenizer ... , ,The FastPrep System consists of ... Matrix and Isolation Kits. Samples are homogenized ... the use of metal probes and shearing ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Biology Products: